Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ligelizumab in uncontrolled allergic asthma
NCT02336425Phase 2Terminated
- Sponsor
- Novartis
- Start
- Sep 2015
- Primary completion
- Mar 2016
- Modality
- Monoclonal Antibodies
- Countries
- 10
01
Overview
Phase 2, randomised, double-blind trial of ligelizumab in allergic asthma (4 arms), sponsored by Novartis. Primary endpoint: Rate of Severe Asthma Exacerbations at 52 weeks. Started Sep 2015; status: terminated.
02
Drugs
ligelizumab
03
Conditions
allergic asthma
Beyond the preview
Go deeper on NCT02336425.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02336425.